A new study has found a surprising link between high levels of methylmalonic acid and the weakening of CD8+ T cells, shedding light on potential pathways through which aging may promote lung cancer progression.
Moffitt Cancer Center researchers have found new insights into how metabolic changes associated with aging can impact immune responses against tumors. Their study, published in Oncogene, explores how increased methylmalonic acid impairs the activation and effector functions of CD8+ T cells, immune cells that play a vital role in fighting cancer.
Researchers found that methylmalonic acid treatment significantly reduced the activity of CD8+ T cells, an important component of the immune response to tumors. The study’s results indicate that methylmalonic acid influences global gene expression in these cells, leading to the downregulation of key pathways involved in immune activation and metabolism.
The study also highlights the role of methylmalonic acid in skewing the tumor microenvironment, affecting not only T cells but also other immune cells, potentially contributing to a more favorable environment for tumor growth and metastasis.
These findings suggest that strategies aimed at reducing methylmalonic acid levels or counteracting its effects on CD8+ T cells could enhance antitumor immunity, particularly in older patients who are at greater risk for lung cancer.
